Articles Related to Multiple Sclerosis
Multiple Sclerosis Disease Modifying Therapy and Cancer risks
Multiple sclerosis (MS) is a chronic inflammatory condition not commonly associated with cancer. Although since 1993 with the
introduction of disease modifying therapies (DMTs), changing the natural history of the disease, cancer risk appears associated with
some of these new therapies. We present the most common risks associated with each DMTs.
DNA Polymerase as Therapeutic Intervention for Treating Patients with Multiple Sclerosis
In recent years, increasing evidence has pointed to the potential role of fibrinolysis in the pathogenesis of MS. Based on hypotheses describing the aggressive autoimmune responses observed in MS patients, a result of impaired between (t-PA and PA1-1) which are a key molecules in both fibrinolysis and extracellular proteolysis. The present study was done to investigate the therapeutic potential of polymerase enzyme in modulating the changes occurred between levels of Tissue- type plasminogen activator (t-PA) and its inhibitor (PAI-1) in patients with multiple sclerosis. A pilot study was carried out on a total of twenty-one patients (17 females, 4 males; aged 22-46 years) with demyelination suggestive of MS and clinically silent T2 brain lesions on magnetic resonance imaging (MRI).
Editorial Board Members Related to Multiple Sclerosis
Rashmi Bansal
Professor
Department of Neuroscience
University of Connecticut Health Center
United States
Department of Neuroscience
University of Connecticut Health Center
United States
Eric Fung
Professor of Pharmacology
Department of Oral Biology
University of Nebraska Medical Center College of Dentistry
United States
Department of Oral Biology
University of Nebraska Medical Center College of Dentistry
United States
Michael P. Namaka
Associate Professor
Faculty of Pharmacy and Medicine
University of Manitoba
Canada
Faculty of Pharmacy and Medicine
University of Manitoba
Canada